Mafalda Oliveira discusses ESR1m ctDNA in MBC patients treated by camizestrant
The European Society for Medical Oncology (ESMO) posted on LinkedIn:
“For ESMO members: Breaking Science in Breast Cancer.
Mafalda Oliveira discusses ESR1m ctDNA in MBC patients treated by camizestrant.
Watch her presentation and other impactful videos on OncologyPRO now.”
Source: The European Society for Medical Oncology (ESMO)/LinkedIn
.
The European Society for Medical Oncology (ESMO) represents over 35,000 oncology professionals across 172 countries and is a key resource for oncology education and information. ESMO’s primary mission is to enhance the quality of cancer care, spanning prevention, diagnosis, palliative care, and patient follow-up. It focuses on educating doctors, cancer patients, and the general public about best practices and the latest advancements in oncology, and advocates for equal access to optimal cancer care for all patients.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023